Analysis of clinical effect of compound α-ketoacid tablets and high-throughput hemodialysis in the treatment of uremic patients
Objective To observe the clinical effect of compound α-ketoacid tablets and high-throughput hemodialysis in the treatment of uremic patients. Methods 60 patients with uremia were divided into an experimental group and a control group using a random number table method,each consisting of 30 cases. The experimental group was given compound α-ketoacid tablets and high-throughput hemodialysis,while the control group received high-throughput hemodialysis. Both groups were compared in terms of treatment effect,incidence of adverse events,nutritional status[Quantitative Subjective Global Assessment (Q-SGA),Malnutrition-Inflammation Score (MIS)],inflammatory factors[interleukin-6 (IL-6),tumor necrosis factor-α (TNF-α),and C-reactive protein (CRP)],immune function indexes (CD3+,CD4+),depression level[Hamilton Depression Scale (HAMD) score],anxiety level[Hamilton Anxiety Scale (HAMA) score],and quality of life[36-Item Short-Form Health Survey (SF-36) score]. Results The total effective rate of treatment of the experimental group (96.67％) was higher than that of the control group (70.00％) (P<0.05). The incidence of adverse events in the experimental group (3.33％) was lower than that in the control group (23.33％) (P<0.05). After 3 months of treatment,the levels of IL-6,TNF-α and CRP were (48.27±12.84) ng/L,(2.03±0.42) ng/ml and (30.26±8.34) mg/L in the experimental group,which were lower than (56.43±13.47) ng/L,(3.25±0.51) ng/ml and (60.39±17.31) mg/L in the control group (P<0.05). After 3 months of treatment,the experimental group had Q-SGA score of (12.36±3.51) points and MIS score of (8.43±1.21) points,which were lower than (16.26±3.24) and (11.39±1.73) points in the control group (P<0.05). After 3 months of treatment,the experimental group had CD3+of (45.46±5.37)％ and CD4+of (34.69±4.38)％,which were higher than (40.13±5.32)％ and (31.15±4.23)％ in the control group (P<0.05). After 3 months of treatment,the experimental group had HAMD score of (9.84±2.13) points and HAMA score of (8.98±2.43) points,which were lower than (13.85±2.26) and (12.71±2.62) points in the control group (P<0.05). After 3 months of treatment,the experimental group had psychological function score of (80.16±4.28) points,material life status score of (81.28±4.61) points,and social function score of (80.13±3.24) points,which were higher than (71.37±4.64),(72.13±4.62),and (70.92±3.13) points in the control group (P<0.05). Conclusion The use of compound α-ketoacid tablets with high-throughput hemodialysis for the treatment of patients with uremia is effective,which can improve the clinical symptoms,inflammatory response and nutritional state and psychological state,enhance immune function and quality of life,and is suitable for widespread promotion.
万方数据
维普
